TY  - BOOK
AU  - Stroup,T.Scott
AU  - Lieberman,Jeffrey A.
TI  - Antipsychotic trials in schizophrenia: the CATIE project 
T2  - Cambridge medicine
SN  - 9780521895330 (hbk.)
U1  - 616.89806 
PY  - 2010///
CY  - Cambridge
PB  - Cambridge University Press
KW  - CATIE Project
KW  - Antipsychotic drugs
KW  - Testing
KW  - Schizophrenia
KW  - Chemotherapy
N1  - Includes bibliographical references and index; Machine generated contents note: Introduction: Rationale for an independent, pragmatic study of antipsychotic treatments Jeffrey Lieberman; 1. Study design and protocol development process Scott Stroup, Joe McEvoy and Jeffrey Lieberman; 2. Statistical considerations Sonia Davis and Gary Koch; 3. Efficacy and effectiveness Joe McEvoy, Scott Stroup and Jeffrey Lieberman; 4. Measures of global effectiveness, cost-effectiveness Bob Rosenheck; 5. Quality of life and recovery Marvin Swartz; 6. Neurocognition Rich Keefe; 7. Vocational outcomes Sandra Resnick et al.; 8. Family outcomes Deborah Perlick et al.; 9. Neurologic side effects Stan Caroff, Del Miller and Bob Rosenheck; 10. Metabolic side effects and risk of cardiovascular disease Jonathan Meyer, Don Goff and Joe McEvoy; 11. Substance abuse Fred Reimherr and Marvin Swartz; 12. Violence Jeff Swanson and Richard van Dorn; 13. Genetics Patrick Sullivan; 14. Human subjects considerations Scott Stroup, Scott Kim and Paul Appelbaum; 15. Pharmacokinetics Bruce Pollock; 16. Implications of the CATIE project on research design and implementation Scott Stroup and Jeffrey Lieberman; 17. Conclusions-impact of the study and implications for dissemination, practice and policy formation Scott Stroup, Bob Rosenheck and Jeffrey Lieberman; Index
ER  -